TCVYX | VMVAX | TCVYX / VMVAX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 15 years | 13 years | - |
Gain YTD | 0.752 | 1.921 | 39% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 3000 | 83% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 576M | 30.9B | 2% |
Annual Yield % from dividends | 0.89 | 2.14 | 41% |
Returns for 1 year | 2.75 | 12.44 | 22% |
Returns for 3 years | 0.10 | 15.34 | 1% |
Returns for 5 years | 18.89 | 38.46 | 49% |
Returns for 10 years | 39.86 | 81.26 | 49% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
KDHSX | 56.44 | -0.07 | -0.12% |
DWS CROCI Equity Dividend S | |||
FSCCX | 32.75 | -0.65 | -1.95% |
Nuveen Small Cap Value I | |||
NGDCX | 27.68 | -0.56 | -1.98% |
Neuberger Berman Large Cap Growth C | |||
OFSFX | 21.39 | -0.52 | -2.37% |
Olstein Strategic Opportunities Adviser | |||
JGRJX | 37.21 | -0.98 | -2.57% |
JPMorgan Growth Advantage R2 |